Semaglutide/Long-acting basal insulin analogue

索玛鲁肽/胰岛素

Report date: 2024/10/10 20:00:04

Base Information

Drug NameSemaglutide/Long-acting basal insulin analogue
Drug Alias Name索马鲁肽/胰岛素287NNC0148-0287+Semaglutide司美格鲁肽/胰岛素LAISemaNNC0148-0287sema
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsYes SemaglutideLong-acting basal insulin analogue
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeA10AB01A10AC01A10AD01 +[5] 
Related LinksN/A